Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US00287Y1091
Ticker ABBV
Company ABBVIE
Currency $
Price
Aware Investor Index (AII) 586.7293
Recommendation STRONG BUY
P/E 26.92
ROE 100.00 %
Capitalization 122,535,960,000 $
Dividend Yield 4.98 %
P/S 3.74
AII Position 10
P/E Position 377
ROE Position 21
Capitalization Position 73
Dividend Yield Position 85
Sales 32,753,000,000 $
10-Year Average Earnings 4,551,700,000 $
Shares Outstanding 1,546,000,000
Equity -8,446,000,000 $
Dividend per Share 3.95 $
Industry Pharmaceutical
Country United States
ABBVIE Investor Relations Web Site http://www.abbvieinvestor.com







Sales:

YEAR MONTH AMOUNT
2018 12 32,753,000,000.00 $
2017 12 28,216,000,000.00 $
2016 12 25,638,000,000.00 $
2015 12 22,859,000,000.00 $
2014 12 19,960,000,000.00 $
2013 12 18,790,000,000.00 $
2012 12 18,380,000,000.00 $
2011 12 17,444,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,214,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 5,687,000,000.00 $
2017 12 5,309,000,000.00 $
2016 12 5,953,000,000.00 $
2015 12 5,144,000,000.00 $
2014 12 1,774,000,000.00 $
2013 12 4,128,000,000.00 $
2012 12 5,275,000,000.00 $
2011 12 3,433,000,000.00 $
2010 12 4,178,000,000.00 $
2009 12 4,636,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 -8,446,000,000.00 $
2017 12 5,097,000,000.00 $
2016 12 4,636,000,000.00 $
2015 12 3,945,000,000.00 $
2014 12 1,742,000,000.00 $
2013 12 4,492,000,000.00 $
2012 12 3,363,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 1,546,000,000
2017 12 1,603,000,000
2016 12 1,631,000,000
2015 12 1,637,000,000
2014 12 1,610,000,000
2013 12 1,604,000,000
2012 12 1,577,000,000

 












Bloomberg News for ABBVIE:



Google News for ABBVIE:

Yahoo Finance - 1 day ago
Why Is AbbVie (ABBV) Up 0.9% Since Last Earnings Report?
A month has gone by since the last earnings report for AbbVie (ABBV). Shares have added about 0.9% in that time frame, outperforming the ...
The EN Herald
3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock
AbbVie (ABBV) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but ...
Mayfield Recorder
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. The stock has seen a price change of -14.92% since the start ...
Tech Know Bits
AbbVie Is Undervalued
AbbVie's (ABBV) stock is under pressure due to the fact that the patent for Humira will be expiring in 2023, and this is a major uncertainty factor ...
Yahoo Finance - 15 May 2019
AbbVie (ABBV) Upgraded to Buy: Here's Why
AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates ...
Yahoo Finance - 15 May 2019
Two stocks I'd tuck away forever: Roku (ROKU), AbbVie (ABBV)
The recent performance of Roku (NASDAQ:ROKU) stock in the market spoke loud and clear to investors as ROKU saw more than 13.95M ...
Seeking Alpha - 14 May 2019
AbbVie launches higher dose Orilissa
AbbVie (NYSE:ABBV) and licensor Neurocrine Biosciences (NASDAQ:NBIX) announce the commercial availability of the 200 mg twice-daily ...
PRNewswire (press release)
AbbVie: No Reason To Throw In The Towel
AbbVie's (ABBV) stock price development has turned into a nightmare for investors it seems. The stock is down 30% from its 52-week high and ...
StreetInsider.com
AbbVie: Value Trap? Maybe, But Here's Why It Can Revive
ABBV has swung quickly from a growth valuation to a depressed one. Yet it tends to beat expectations, and reported a beat-and-raise Q1 last ...
Yahoo Finance - 29 Apr 2019
AbbVie Grabs FDA Approval In HCV, Faces Several Risks
AbbVie (ABBV) announced that the FDA had approved its drug Mavyret to treat children and adolescents with Hepatitis C. This FDA approval ...


Back